Pricing Log in Create free account
Saturday 31 October 2026 Export SNY’s income statement to Excel — free account

Sanofi

SNY Healthcare Drug Manufacturers General

Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024. In the quarter to June 2026, revenue grew 17.4%, EPS fell 90.8%, free cash flow fell 45.1% and total debt rose 8.23%, each against the same quarter a year earlier. Dividend growth for three consecutive years.

44.43 1.30 +3.01%
Market cap
$102.8B
P/E
23.3×
Fwd P/E
—
Dividend yield
5.45%
F-score
7/9
Altman Z
2.50
Beneish M
−2.63
Dividend safety
54/100
Overview Business Profile Financial Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.55%

Capital & Financial Ratios $m

Market Cap 102,800.00
Revenue 56,955.87
Net Income 4,505.89
Free Cash Flow 14,542.46
Net Debt 17,814.89
Current Ratio 0.99 (below 1: weak)
Debt/Equity 0.31 (at or below 0.5: strong)
P/E ratio 23.26
Fwd P/E —
P/S ratio 1.87
P/B ratio 1.31
Past 5Y EPS Growth (8.39%) (below 0%: weak)
This Y EPS Growth 3.50%
Next Y EPS Growth 6.55%
Next Y revenue growth —
Next 5Y EPS Growth 5.96%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.2×, against a ten-year median of 2.6×; over the ten years it ranged from 1.8× in 2022 to 3.4× in 2017.
P/E against its own 10 years 83.95%
10-year low 10-year high
P/S against its own 10 years 12.85%
10-year low 10-year high
P/B against its own 10 years 4.19%
10-year low 10-year high
EV/Sales against its own 10 years 21.45%
10-year low 10-year high
EV/FCF against its own 10 years 64.23%
10-year low 10-year high

Dividends

Payout Ratio 1.27
Annual Dividend Rate 2.42
Annual Dividend Yield 5.45%
total individual payouts
2026 2.42
2.42
2025 2.20
2.20
2024 2.04
2.04
2023 1.90
1.90
2022 1.92
1.75
0.18
2021 1.93
1.93
2020 1.70
1.70
2019 1.72
1.72
2018 1.79
1.79
2017 1.64
1.64
2016 1.66
1.66
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 9,427 8,052 8,663 7,383
Receivables 9,550 9,091 9,964 10,704
Inventory 10,462 10,205 11,556 12,937
Other 3,756 4,140 4,600 4,979
33,194 46,084 35,019 36,651
2023 2024 2025 Q'26
Payables 7,931 8,171 8,328 8,313
ST’ Debt 2,213 4,555 4,913 8,169
Other 15,097 15,488 17,610 19,122
26,185 31,556 32,070 37,125

Compound Annual Growth %

10y 5y 3y
Sales 3.16% 4.37% 3.39%
Cash Flow 2.83% 7.41% 3.12%
Earnings 6.38% (8.87%) 0.08%
Book Value 2.30% 2.38% 0.82%

Earnings Trends EPS, adjusted, against the consensus

Jun 2026 Estimate 1.10 Actual 1.21

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Sep 2025 1.60 1.70 Beat by 0.10
Dec 2025 0.84 0.89 Beat by 0.05
Mar 2026 1.06 1.10 Beat by 0.04
Jun 2026 1.10 1.21 Beat by 0.11
Sep 2026 1.63 — Reports 30 October 2026

EPS $

Mar Jun Sep Dec Year
’26 0.78 0.17 — — —
’25 0.80 1.84 1.34 (0.38) 3.62
’24 0.49 0.48 1.23 0.19 2.48
’23 0.86 0.63 1.11 (0.24) 2.33
’22 0.90 0.50 0.84 1.30 3.51
’21 0.75 2.63 1.09 3.11 2.94
’20 0.74 8.29 0.91 2.96 5.61
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 13,160 14,301 — — —
’25 11,173 12,186 15,394 14,100 52,854
’24 12,071 12,255 15,567 8,029 47,922
’23 11,660 11,648 13,821 13,138 50,266
’22 11,281 11,432 13,233 11,876 47,822
’21 10,713 20,637 12,770 23,211 46,348
’20 10,277 19,303 11,548 23,285 42,687
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — 5,398 — — —
’25 2,205 1,831 — 12,163 12,163
’24 — 1,532 — 9,827 9,827
’23 — 3,885 — 11,102 11,102
’22 — 3,984 — 11,090 11,090
’21 — 5,728 — 6,555 12,449
’20 — 4,411 — 4,349 8,509
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — 5,398 — — —
’25 2,205 1,831 — 12,163 9,118
’24 — 1,532 — 9,827 7,950
’23 — 3,885 — 11,102 8,928
’22 — 3,984 — 11,090 10,339
’21 — 5,728 — 6,555 10,881
’20 — 4,411 — 4,349 7,143
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Price, $
Price, $ Low 36.81 39.42 37.43 40.00 37.62 45.17 36.91 42.63 45.22 44.62 +2.2% ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
High 44.50 50.65 45.86 50.90 55.00 54.26 58.10 57.82 58.97 60.12 +3.4% ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
People
People Employees 106,859 106,566 104,226 100,409 99,412 95,442 91,573 86,088 82,878 74,846 (3.9%) ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
Revenue/emp, $m 0.36 0.38 0.40 0.42 0.43 0.49 0.52 0.58 0.58 0.71 +7.8% ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
Income, $m
Income, $m Revenue 38,408 40,921 42,135 42,147 42,687 46,348 47,822 50,266 47,922 52,854 +3.6% — — — —
Gross margin, % 69.17 67.93 67.95 68.18 67.47 68.72 69.83 69.35 70.18 72.07 +2.9 pt
EBT 6,283 6,251 5,202 3,161 15,768 9,226 10,981 7,742 7,248 6,986 +1.2%
EBT margin, % 16.36 15.27 12.35 7.50 36.94 19.91 22.96 15.40 15.12 13.22 (3.1) pt
Net income 5,211 9,533 5,085 3,143 14,066 7,362 8,820 5,844 5,947 5,588 +0.8%
Depreciation 3,653 4,166 5,053 8,346 4,208 3,965 3,603 5,186 3,880 6,424 +6.5%
Per share, $
Per share, $ Revenue 14.93 16.28 16.89 16.86 17.03 18.50 19.10 20.08 19.15 21.65 +4.2%
Earnings 2.03 1.76 2.04 1.24 5.61 2.94 3.52 2.33 2.48 3.62 +6.6%
Cash flow 3.37 3.32 2.63 3.47 3.39 4.97 4.43 4.43 3.93 4.98 +4.4%
Capex (0.81) (0.64) 0.09 (0.27) (0.54) (0.63) (0.30) (0.87) (0.75) (1.25) +5.0%
Free cash flow 2.56 2.68 2.71 3.20 2.85 4.34 4.13 3.57 3.18 3.74 +4.3%
Book value 24.82 26.20 27.95 26.48 28.77 32.60 31.62 32.15 33.66 33.24 +3.3%
Shares, m 2,573 2,514 2,494 2,500 2,507 2,505 2,504 2,503 2,503 2,441 (0.6%)
Valuation, ×
Valuation, × P/E 20.11 24.17 12.01 12.95 3.74 6.59 13.80 21.19 20.08 13.46 14.8
P/S 2.75 2.66 2.06 2.04 1.91 1.87 2.57 2.49 2.52 2.24 2.3
P/B 1.65 1.65 1.61 1.90 1.58 1.62 1.55 1.56 1.43 1.46 1.6
EV/Sales 2.99 2.81 2.44 2.33 2.10 2.08 2.70 2.66 2.71 2.47 2.5
EV/FCF 8.24 6.69 6.84 8.39 8.80 7.52 5.01 5.16 6.33 7.02 7.0
Cash, $m
Cash, $m Operating cash flow 8,674 8,340 6,551 8,673 8,509 12,449 11,090 11,102 9,827 12,163 +3.8%
Capex (2,074) (1,606) 220 (663) (1,366) (1,568) (751) (2,174) (1,876) (3,045) +4.4%
Free cash flow 6,600 6,734 6,771 8,010 7,143 10,881 10,339 8,928 7,950 9,118 +3.7%
Balance, $m
Balance, $m Working capital 11,346 12,315 8,507 9,218 16,512 10,966 10,601 7,009 14,528 2,950 (13.9%)
Total debt 20,560 17,634 29,100 27,647 25,715 24,024 20,051 17,741 17,314 21,033 +0.3%
Net debt 9,191 5,975 20,921 17,089 9,820 12,077 6,632 8,314 9,262 12,370 +3.4%
Shareholders’ equity 63,877 65,849 69,720 66,201 72,133 81,671 79,180 80,472 84,249 81,133 +2.7%
Returns, %
Returns, % ROA 4.54 8.34 4.16 2.44 10.94 5.39 6.40 4.32 4.29 6.16 +1.6 pt
ROIC 6.49 6.15 4.30 5.46 12.50 6.56 7.81 6.75 5.49 6.57 +0.1 pt
ROE 8.11 14.70 7.50 4.62 20.34 9.57 10.97 7.32 7.31 10.69 +2.6 pt
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Sanofi vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AZN AstraZeneca PLC $270.5B 27.6× 22.4× +6.41% (above 0%: growing) +1.90% (above 0%: growing) −107.45% (below 0%: shrinking) 83.60% 20.57% Compare
AMGN Amgen Inc. $249.1B 28.7× 27.9× +9.53% (above 0%: growing) +65.41% (above 0%: growing) +82.57% (above 0%: growing) 72.04% 34.95% Compare
GILD Gilead Sciences, Inc. $205.4B — (loss-making) — (loss-making) +10.18% (above 0%: growing) n/m +376.81% (above 0%: growing) 79.76% (133.21%) Compare
PFE Pfizer Inc. $170.7B 40.1× 18.6× +2.60% (above 0%: growing) n/m +125.17% (above 0%: growing) 72.78% 20.38% Compare
NVO Novo Nordisk A/S $131.0B 9.8× — +4.47% (above 0%: growing) −18.68% (below 0%: shrinking) +71.57% (above 0%: growing) 78.21% 34.48% Compare
BMY Bristol Myers Squibb Company $125.4B 13.8× 11.6× +5.74% (above 0%: growing) +153.13% (above 0%: growing) −13.16% (below 0%: shrinking) 71.28% 31.50% Compare
SNY Sanofi $102.8B 23.3× — +17.35% (above 0%: growing) −90.76% (below 0%: shrinking) −45.06% (below 0%: shrinking) 75.47% 17.48%
GSK GSK PLC Sponsored ADR $97.6B 15.4× 14.3× +5.81% (above 0%: growing) −69.47% (below 0%: shrinking) +54.83% (above 0%: growing) 73.05% 5.72% Compare
BIIB Biogen Inc. $36.9B 44.8× 42.9× +3.42% (above 0%: growing) −84.76% (below 0%: shrinking) +103.28% (above 0%: growing) 71.60% 5.52% Compare
Median of peers $150.8B 27.6× 20.5× +5.77% −8.39% +77.07% 72.92% 20.48%

All 21 Drug Manufacturers General stocks →

Sanofi (SNY) Latest News

30 Oct

Impact 4 ·
Impact 4 ·
Impact 3 ·
Impact 3 ·
Impact 3 ·
Impact 3 ·

29 Oct

Impact 4 ·
Impact 4 ·
Impact 4 ·
Impact 3 ·

26 Oct

Impact 4 ·
Impact 4 ·
Impact 4 ·

21 Oct

Impact 4 ·
Impact 4 ·

20 Oct

Impact 4 ·
Impact 4 ·
Impact 4 ·
Impact 3 ·

19 Oct

Impact 4 ·
Impact 4 ·
Impact 4 ·

18 Oct

Impact 3 ·
Impact 3 ·
Impact 3 ·

17 Oct

Impact 4 ·

15 Oct

Impact 4 ·
Impact 3 ·
Impact 3 ·
Impact 3 ·
stockrow.com/SNY · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com